Intimation of trading approval obtained from Stock Exchanges for 81,24,698 Equity Shares of RS. 10/- each…
As filed · Intimation of trading approval obtained from Stock Exchanges for 81,24,698 Equity Shares of RS. 10/- each issued pursuant to the approved Scheme of Amalgamation
What happened
FactIntimation of trading approval obtained from Stock Exchanges for 81,24,698 Equity Shares of RS. Shares of ₹10/- each issued pursuant to the approved Scheme of Amalgamation. pursuant to the Scheme of Arrangement for the Amalgamation of Ind-Swift Limited (Transferor.
Why it matters
CapitSignal interpretationA merger fixes a share-exchange ratio, which permanently sets how much of the combined company existing holders own.
What management said before
Prior statements by this company that CapitSignal has recorded changing.
Demand
DelayedIn the second quarter we are expecting a major push from Arrotex on that Macrogol new molecule which we launched.
And in third and fourth quarter we see a lot of progress coming from Ibuprofen and Clarithromycin granules.
Change
FactImplication
CapitSignal interpretationWatch next
Fact- Swap ratio and its valuation basis
- Regulatory and NCLT approvals required
- Appointed date
- We expect FY27 to witness revenue growth of more than 50%. (management committed by FY27)
- A key milestone was the commercialization of the Viatris (USA), Manx (UK) and Arrotex (Australia) CDMO partner (management committed by FY27)
Evidence
- Intimation of trading approval obtained from Stock Exchanges for 81,24,698 Equity Shares of RS. 10/- each issued pursuant to the approved Scheme of Amalgamation(opens the original filing in a new tab)
- Earlier statement · Q1 FY27
- Latest statement · Q1 FY27
- Earlier statement · Q1 FY27
How CapitSignal classified this
- Reasoning:
- MERGER base 74; +2 corroborating keywords; +5 quantified amount; matched on subject
- Matched on:
- the filing's own subject line
- Confidence in the event type:
- 90%